BR112013029269A8 - combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2 - Google Patents

combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2

Info

Publication number
BR112013029269A8
BR112013029269A8 BR112013029269A BR112013029269A BR112013029269A8 BR 112013029269 A8 BR112013029269 A8 BR 112013029269A8 BR 112013029269 A BR112013029269 A BR 112013029269A BR 112013029269 A BR112013029269 A BR 112013029269A BR 112013029269 A8 BR112013029269 A8 BR 112013029269A8
Authority
BR
Brazil
Prior art keywords
type
patients
diabetes patients
diabetes
pharmaceutical combination
Prior art date
Application number
BR112013029269A
Other languages
English (en)
Other versions
BR112013029269A2 (pt
Inventor
Boka Gabor
Silvestre Louise
Miossec Patrick
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BR112013029269A2 publication Critical patent/BR112013029269A2/pt
Publication of BR112013029269A8 publication Critical patent/BR112013029269A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients abstract: the present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients. **************************************** tradução do resumo resumo patente de invenção: "combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2". a presente invenção refere-se a uma combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2.
BR112013029269A 2011-05-13 2012-05-11 combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2 BR112013029269A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166058 2011-05-13
PCT/EP2012/058745 WO2012156296A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients

Publications (2)

Publication Number Publication Date
BR112013029269A2 BR112013029269A2 (pt) 2016-11-29
BR112013029269A8 true BR112013029269A8 (pt) 2018-01-16

Family

ID=46146838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029269A BR112013029269A8 (pt) 2011-05-13 2012-05-11 combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2

Country Status (11)

Country Link
US (1) US8735349B2 (pt)
EP (1) EP2707016A1 (pt)
JP (1) JP6121403B2 (pt)
KR (1) KR20140043756A (pt)
CN (2) CN107496907A (pt)
AU (1) AU2012257847B2 (pt)
BR (1) BR112013029269A8 (pt)
CA (1) CA2835496C (pt)
MX (1) MX366090B (pt)
RU (2) RU2761624C2 (pt)
WO (1) WO2012156296A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
TWI397617B (zh) 2010-02-12 2013-06-01 Masahiro Hoshino Metal silicon purification device
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
WO2012104342A1 (en) * 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN114939156A (zh) 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20020177151A1 (en) 2001-02-26 2002-11-28 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
NZ539625A (en) 2002-09-27 2007-11-30 Martek Biosciences Corp Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
CN101130090B (zh) * 2006-08-22 2010-05-12 复旦大学 Brsk2在制备抗糖尿病药物中的应用
CL2008000133A1 (es) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
WO2008111956A2 (en) * 2007-03-09 2008-09-18 Symcopeia Company Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
ES2553593T3 (es) 2009-11-13 2015-12-10 Sanofi-Aventis Deutschland Gmbh Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2
AU2009238272B2 (en) * 2009-11-13 2014-05-08 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin

Also Published As

Publication number Publication date
MX366090B (es) 2019-06-27
MX2013013200A (es) 2014-10-24
KR20140043756A (ko) 2014-04-10
AU2012257847B2 (en) 2017-05-25
EP2707016A1 (en) 2014-03-19
US20130023467A1 (en) 2013-01-24
RU2017143385A (ru) 2019-02-14
JP6121403B2 (ja) 2017-04-26
CA2835496A1 (en) 2012-11-22
RU2013155473A (ru) 2015-06-20
WO2012156296A8 (en) 2013-02-21
CN107496907A (zh) 2017-12-22
BR112013029269A2 (pt) 2016-11-29
WO2012156296A1 (en) 2012-11-22
JP2014514355A (ja) 2014-06-19
CA2835496C (en) 2022-06-07
CN103648520A (zh) 2014-03-19
RU2761624C2 (ru) 2021-12-13
RU2017143385A3 (pt) 2021-03-04
US8735349B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112013031268A8 (pt) polipeptídeos
BR112014005440A2 (pt) composição compreendendo n-acetilcisteína e/ou lisozima gastroprotegida microencapsulada em associação com bactérias probióticas capazes de restaurar o efeito de barreira do próprio estômago que é perdido durante o tratamento farmacológico de hiperacidez gástrica
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112014026906A2 (pt) formulação compreendendo etanolamida de ácido caprílico e/ou etanolamida de ácido cáprico em combinação com um sal de alumínio e seu uso
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015012197A2 (pt) terapia de combinação
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
BR112013004756A2 (pt) uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
BR112014003640A8 (pt) métodos para perda de peso e composições cetogênicas
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112013026573A2 (pt) fórmula de lactente para uso na prevenção de doenças cardiovasculares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]